Latest Period
Q4 2025
Security Snapshot
Nautilus Biotechnology, Inc. - Common stock, par value $0.0001 per share (NAUT) Institutional Ownership
CUSIP: 63909J108
13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026
Institutions Reporting
66
Shares (Excl. Options)
58,296,547
Price
$1.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common stock, par value $0.0001 per share
- Symbol
- NAUT on Nasdaq
- Shares outstanding
- 130,367,883
- Price per share
- $3.88
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 58,296,547
- Total reported value
- $113,673,004
- % of total 13F portfolios
- 0%
- Share change
- +388,451
- Value change
- +$1,369,133
- Number of holders
- 66
- Price from insider filings
- $3.88
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NAUT - Nautilus Biotechnology, Inc. - Common stock, par value $0.0001 per share is tracked under CUSIP 63909J108.
- 66 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 66 to 10 between Q4 2025 and Q1 2026.
- Reported value moved from $113,673,004 to $1,201,952.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 66 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 63909J108?
CUSIP 63909J108 identifies NAUT - Nautilus Biotechnology, Inc. - Common stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 63909J108:
Significant Owners of Nautilus Biotechnology, Inc. - Common stock, par value $0.0001 per share (NAUT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Mallick Parag | 18% | +1.2% | $48,724,008 | +$633,960 | 22,557,411 | +1.3% | Parag Mallick | 02 Mar 2026 |
| Patel Sujal M | 16% | +3.8% | $45,899,924 | +$2,056,823 | 21,249,965 | +4.7% | Sujal Patel | 02 Mar 2026 |
| PERCEPTIVE ADVISORS LLC | 10% | +1% | $11,149,148 | +$192,185 | 12,815,113 | +1.8% | Perceptive Advisors LLC | 20 Jun 2025 |
As of 31 Dec 2025, 66 institutional investors reported holding 58,296,547 shares of Nautilus Biotechnology, Inc. - Common stock, par value $0.0001 per share (NAUT). This represents 45% of the company’s total 130,367,883 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Nautilus Biotechnology, Inc. - Common stock, par value $0.0001 per share (NAUT) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| a16z Capital Management, L.L.C. | 14% | 17,653,917 | 0% | 2.2% | $34,425,138 |
| PERCEPTIVE ADVISORS LLC | 9.7% | 12,594,211 | 0% | 0.45% | $24,558,711 |
| Cercano Management LLC | 5.5% | 7,172,985 | 0% | 0.54% | $13,987,321 |
| Madrona Venture Group, LLC | 4.6% | 6,020,770 | 0% | 53% | $11,741,000 |
| VANGUARD GROUP INC | 2% | 2,598,223 | +6.8% | 0% | $5,066,536 |
| Comprehensive Financial Management LLC | 1.7% | 2,207,619 | 0% | 0.13% | $4,304,857 |
| AMAZON COM INC | 1.1% | 1,457,055 | 0% | 0.08% | $2,841,257 |
| Clarius Group, LLC | 0.93% | 1,209,646 | 0% | 0.13% | $2,358,810 |
| MILLENNIUM MANAGEMENT LLC | 0.78% | 1,019,996 | +5.4% | 0% | $1,988,992 |
| SENTINEL TRUST CO LBA | 0.58% | 750,000 | 0.14% | $1,462,000 | |
| Tikvah Management LLC | 0.56% | 726,895 | 0% | 0.39% | $1,417,445 |
| ACADIAN ASSET MANAGEMENT LLC | 0.47% | 611,984 | +152% | 0% | $1,187,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.43% | 560,909 | +1.3% | 0% | $1,094,035 |
| GOLDMAN SACHS GROUP INC | 0.23% | 297,437 | +153% | 0% | $580,002 |
| DIMENSIONAL FUND ADVISORS LP | 0.22% | 285,439 | -22% | 0% | $556,319 |
| RENAISSANCE TECHNOLOGIES LLC | 0.2% | 259,900 | -74% | 0% | $506,805 |
| Alyeska Investment Group, L.P. | 0.19% | 253,468 | 0% | 0% | $494,263 |
| JANE STREET GROUP, LLC | 0.16% | 206,837 | +40% | 0% | $403,332 |
| STATE STREET CORP | 0.15% | 201,255 | +13% | 0% | $392,447 |
| HILLMAN CO | 0.15% | 200,000 | 0% | 0.14% | $390,000 |
| BlackRock, Inc. | 0.15% | 189,431 | -6% | 0% | $369,391 |
| Crewe Advisors LLC | 0.1% | 136,052 | 0% | 0.02% | $265,302 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.1% | 130,000 | +4% | 0.01% | $253,500 |
| GSA CAPITAL PARTNERS LLP | 0.1% | 124,051 | -52% | 0.02% | $242,000 |
| Qube Research & Technologies Ltd | 0.09% | 123,121 | +138% | 0% | $240,086 |
Institutional Holders of Nautilus Biotechnology, Inc. - Common stock, par value $0.0001 per share (NAUT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 309,864 | $1,201,952 | +$194 | $3.88 | 10 |
| 2025 Q4 | 58,296,547 | $113,673,004 | +$1,369,133 | $1.95 | 66 |
| 2025 Q3 | 57,899,311 | $48,912,774 | -$1,403,087 | $0.84 | 65 |
| 2025 Q2 | 59,755,012 | $43,314,600 | -$2,449,905 | $0.72 | 67 |
| 2025 Q1 | 62,775,437 | $54,045,644 | -$1,026,756 | $0.86 | 86 |
| 2024 Q4 | 63,869,661 | $107,299,374 | -$821,201 | $1.68 | 86 |
| 2024 Q3 | 64,190,100 | $182,943,834 | +$1,290,455 | $2.85 | 81 |
| 2024 Q2 | 63,999,578 | $149,759,950 | +$1,608,547 | $2.34 | 75 |
| 2024 Q1 | 63,240,413 | $185,925,873 | -$499,885 | $2.94 | 70 |
| 2023 Q4 | 63,424,716 | $189,647,655 | +$5,847,645 | $2.99 | 74 |
| 2023 Q3 | 45,082,721 | $142,463,072 | +$769,963 | $3.16 | 74 |
| 2023 Q2 | 44,814,450 | $173,427,573 | +$1,498,150 | $3.87 | 74 |
| 2023 Q1 | 44,499,314 | $123,255,982 | -$1,802,223 | $2.77 | 72 |
| 2022 Q4 | 46,081,461 | $82,942,228 | -$2,657,044 | $1.80 | 78 |
| 2022 Q3 | 56,460,432 | $119,696,429 | -$2,490,160 | $2.12 | 77 |
| 2022 Q2 | 57,502,356 | $154,669,821 | +$297,442 | $2.69 | 80 |
| 2022 Q1 | 56,024,124 | $243,509,430 | -$20,551,922 | $4.34 | 79 |
| 2021 Q4 | 41,913,282 | $217,115,889 | +$1,259,255 | $5.18 | 77 |
| 2021 Q3 | 40,974,903 | $245,092,558 | +$9,814,243 | $6.14 | 68 |
| 2021 Q2 | 33,010,619 | $331,901,744 | +$331,901,478 | $10.10 | 55 |